NCT06225115View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

PHASE1CompletedINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

December 21, 2023

Primary Completion Date

October 7, 2024

Study Completion Date

October 7, 2024

Conditions

Cognitive DysfunctionSchizophrenia

Interventions

DRUG

KYN-5356

KYN-5356, oral tablet

DRUG

placebo

placebo, oral tablet

Trial Locations (1)

91206

Parexel Los Angeles Early Phase Clinical Unit, Glendale

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

Kynexis B.V.

INDUSTRY